Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Feb 24;142:83–122. doi: 10.1016/j.antiviral.2017.02.014

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Published by Elsevier B.V.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 2 — Tertiary structure of HCV NS3/4A protease and structural formulas of approved or experimental NS3/4A inhibitors from (1) to (18). The tertiary structure of NS3/4A protease in complex with simeprevir (PDB codes: 3KEE and 4B76) is shown on top. HCV NS3 and NS4A proteins are displayed in orange and pink, respectively. Beneath the NS3/4A protein, chemical structures of approved and experimental NS3/4A inhibitors (Table 20) are demonstrated. Blue arrows indicate the optimization from initial compounds to FDA-approved compounds such as boceprevir (Njoroge et al., 2008), telaprevir (Kwong et al., 2011), simeprevir (Rosenquist et al., 2014), and grazoprevir (Harper et al., 2012, Liverton et al., 2008). Red structures indicate the differences between initial compounds and FDA- approved compounds.

Fig. 2 — Tertiary structure of HCV NS3/4A protease and structural formulas of approved or experimental NS3/4A inhibitors from (1) to (18). The tertiary structure of NS3/4A protease in complex with simeprevir (PDB codes: 3KEE and 4B76) is shown on top. HCV NS3 and NS4A proteins are displayed in orange and pink, respectively. Beneath the NS3/4A protein, chemical structures of approved and experimental NS3/4A inhibitors (Table 20) are demonstrated. Blue arrows indicate the optimization from initial compounds to FDA-approved compounds such as boceprevir (Njoroge et al., 2008), telaprevir (Kwong et al., 2011), simeprevir (Rosenquist et al., 2014), and grazoprevir (Harper et al., 2012, Liverton et al., 2008). Red structures indicate the differences between initial compounds and FDA- approved compounds.

HHS Vulnerability Disclosure